AngioDynamics Announces Agreement with Transonic Systems Corporation.Business Editors/Health Writers QUEENSBURY, N.Y.--(BUSINESS WIRE)--Dec. 13, 2002 AngioDynamics, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of E-Z-EM, Inc., (AMEX AMEX See: American Stock Exchange :EZM) today announced that it has entered into a worldwide agreement with Transonic transonic in ultrasonography, the complete transmission of sound so the image appears black; anechoic; echolucent. Systems Corporation for distribution of the Transonic Endovascular Flowmeter See flow meter. System. The system will be marketed under the AngioDynamics brand name, and consists of the AngioDynamics Flowmeter(TM) and the Reo-Cath(TM) Dilution Flow Catheter. Under the terms of the five-year agreement, AngioDynamics will distribute both products globally with exclusive rights in the United States. The products have been previously cleared by the U.S. Food and Drug Administration and comparable foreign agencies. The AngioDynamics Flowmeter(TM) System measures flow rates in the bloodstream, providing physicians with the means to monitor the success of interventional vascular procedures such as hemodialysis catheter placement, stenting procedures, and peripheral balloon angioplasty balloon angioplasty: see under angioplasty. . For the first time interventionalists will have detailed information concerning flow rates within the body and provides a much needed tool to assure procedural quality. Commenting on the agreement, Cornelius Drost, Founder and President of Transonic Systems said, "This relationship combines Transonic Systems' strength in hemodynamic he·mo·dy·nam·ics n. (used with a sing. verb) The study of the forces involved in the circulation of blood. he flow meters with AngioDynamics' marketing expertise in interventional radiology. Flow has long been documented in the hemodialysis clinics using our system as an important predictor of graft failure. AngioDynamics can now help extend the application of flow measurement into the radiology suite." Commenting on the announcement, Eamonn P. Hobbs, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. for AngioDynamics said, "The AngioDynamics Flowmeter(TM) System is an innovative diagnostic tool that we believe will be essential to successful vascular access management in the future. As one of the leading suppliers of dialysis catheters in the United States, AngioDynamics is well positioned to bring this important new tool to our customers. We are excited to be working with Transonic Systems in what we hope will be a long and mutually rewarding relationship." For additional information, please contact Don Geer at 1-800-772-6446 x167, or at dgeer@angiodynamics.com, or visit the AngioDynamics web site at www.angiodynamics.com. About E-Z-EM E-Z-EM, Inc. (www.ezem.com) is a leading supplier of products used by radiologists, gastroenterologists and speech language pathologists for the diagnostic imaging of diseases and disorders of the GI tract, ranging from swallowing disorders (dysphagia dysphagia /dys·pha·gia/ (-fa´jah) difficulty in swallowing. dys·pha·gia or dys·pha·gy n. Difficulty in swallowing or inability to swallow. ) to colorectal cancers. E-Z-EM also is a third-party contract manufacturer of diagnostic contrast media, pharmaceuticals, non-prescription healthcare products, and defense decontaminants. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading supplier of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and therapeutic treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic Fluoroscopic (fluoroscopy) An x-ray procedure that produces immediate images and motion on a screen. The images look like those seen at airport baggage security stations. Mentioned in: Hypotonic Duodenography procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended August 31, 2002, as well as its Annual Report on Form 10-K for the year ended June 1, 2002, may affect the actual results achieved by the Company |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion